🚀 VC round data is live in beta, check it out!
Prostatype Genomics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Prostatype Genomics and similar public comparables like Brainscan, Genetic Analysis, Spermosens, Elite Diagnostic and more.
Prostatype Genomics Overview
About Prostatype Genomics
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
Founded
2007
HQ
Employees
6
Website
Financials (FY)
EV
$5M
Prostatype Genomics Financials
Prostatype Genomics reported last fiscal year revenue of $65K and negative EBITDA of ($4M).
In the same fiscal year, Prostatype Genomics generated $65K in gross profit, ($4M) in EBITDA losses, and had net loss of ($5M).
Prostatype Genomics P&L
In the most recent fiscal year, Prostatype Genomics reported revenue of $65K and EBITDA of ($4M).
Prostatype Genomics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $65K | XXX | XXX | XXX |
| Gross Profit | — | XXX | $65K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 100% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($4M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (6852%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (6555%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($5M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (7492%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Prostatype Genomics Stock Performance
Prostatype Genomics has current market cap of $6M, and enterprise value of $5M.
Market Cap Evolution
Prostatype Genomics' stock price is $0.10.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5M | $6M | 0.3% | XXX | XXX | XXX | $-0.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialProstatype Genomics Valuation Multiples
Prostatype Genomics trades at 71.7x EV/Revenue multiple, and (1.0x) EV/EBITDA.
Prostatype Genomics Financial Valuation Multiples
As of April 20, 2026, Prostatype Genomics has market cap of $6M and EV of $5M.
Equity research analysts estimate Prostatype Genomics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Prostatype Genomics has a P/E ratio of (1.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6M | XXX | $6M | XXX | XXX | XXX |
| EV (current) | $5M | XXX | $5M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 71.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.0x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (1.1x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 71.7x | XXX | XXX | XXX |
| P/E | — | XXX | (1.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Prostatype Genomics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Prostatype Genomics Margins & Growth Rates
Prostatype Genomics' revenue in the last fiscal year grew by 198%.
Prostatype Genomics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.
Prostatype Genomics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 198% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (6852%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 9% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 246% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 6655% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Prostatype Genomics Public Comps
See public comps and valuation multiples for other Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Prostatype Genomics | XXX | XXX | XXX | XXX | XXX | XXX |
| Brainscan | XXX | XXX | XXX | XXX | XXX | XXX |
| Genetic Analysis | XXX | XXX | XXX | XXX | XXX | XXX |
| Spermosens | XXX | XXX | XXX | XXX | XXX | XXX |
| Elite Diagnostic | XXX | XXX | XXX | XXX | XXX | XXX |
| Level Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Prostatype Genomics M&A Activity
Prostatype Genomics acquired XXX companies to date.
Last acquisition by Prostatype Genomics was on XXXXXXXX, XXXXX. Prostatype Genomics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Prostatype Genomics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialProstatype Genomics Investment Activity
Prostatype Genomics invested in XXX companies to date.
Prostatype Genomics made its latest investment on XXXXXXXX, XXXXX. Prostatype Genomics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Prostatype Genomics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Prostatype Genomics
| When was Prostatype Genomics founded? | Prostatype Genomics was founded in 2007. |
| Where is Prostatype Genomics headquartered? | Prostatype Genomics is headquartered in Sweden. |
| How many employees does Prostatype Genomics have? | As of today, Prostatype Genomics has over 6 employees. |
| Is Prostatype Genomics publicly listed? | Yes, Prostatype Genomics is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Prostatype Genomics? | Prostatype Genomics trades under PROGEN ticker. |
| When did Prostatype Genomics go public? | Prostatype Genomics went public in 2020. |
| Who are competitors of Prostatype Genomics? | Prostatype Genomics main competitors are Brainscan, Genetic Analysis, Spermosens, Elite Diagnostic. |
| What is the current market cap of Prostatype Genomics? | Prostatype Genomics' current market cap is $6M. |
| What is the current revenue of Prostatype Genomics? | Prostatype Genomics' last fiscal year revenue is $65K. |
| What is the current EV/Revenue multiple of Prostatype Genomics? | Current revenue multiple of Prostatype Genomics is 71.7x. |
| Is Prostatype Genomics profitable? | No, Prostatype Genomics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.